Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CHRONIC LYMPHOCYTIC LEUKEMIA

Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Progression Free Survival.

References

  1. Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33.

    CAS  Article  Google Scholar 

  2. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.

    CAS  Article  Google Scholar 

  3. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134:111–22.

    CAS  Article  Google Scholar 

  4. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    CAS  Article  Google Scholar 

  5. Maddocks KFJ, Adritsos L, Awan F, Woyach JA, Grever MR, Stefanos M, et al. editors. A Phase II study of the BTK inhibitor ibrutinib in genetic risk-stratified relapsed and refractory patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Milan, Italy: European Hematology Association Annual Meeting; 2014.

  6. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    Article  Google Scholar 

  7. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126:842–50.

    CAS  Article  Google Scholar 

  8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.

    CAS  Article  Google Scholar 

  9. Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39:576–85.

    CAS  Article  Google Scholar 

  10. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205–16.

    CAS  Article  Google Scholar 

  11. Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138:2372–82.

    CAS  Article  Google Scholar 

  12. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437–43.

    CAS  Article  Google Scholar 

  13. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–7.

    Article  Google Scholar 

  14. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.

    CAS  Article  Google Scholar 

  15. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–506.

    CAS  Article  Google Scholar 

Download references

Funding

The study is funded in part through R01CA177292, R35CA197734, the D Warren Brown Foundation, and Pelotonia. JAW and KAR are Scholars of the Leukemia and Lymphoma Society.

Author information

Authors and Affiliations

Authors

Contributions

AMS and JAW designed the study; AMS and JAW collected the data; YH performed statistical analyses; YH confirmed the accuracy of the data and compiled it for analysis; and all authors were involved in manuscript preparation and approved the final version prior to submission.

Corresponding author

Correspondence to Jennifer A. Woyach.

Ethics declarations

Competing interests

KM has consulted with Acerta, AstraZeneca, Pharmacyclics, Beigene, Loxo, Lilly, Genentech, Morphosys, Celgene, BMS, Kite. KAR received research funding from Genentech, AbbVie, and Janssen, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, AbbVie, Genentech, Pharmacyclics, and Beigene, and received travel funding from AstraZeneca. SJ has consulted for Kite, Novartis, Juno, Takeda, CRISPR Therapeutics and has received research funding from Kite, Novartis, Juno, Caribou. ASK has consulted for Abbvie, Beigene, Bristol-Myers Squibb, and Janssen. MRG has received consult funding from Pharmacyclics, Astra Zeneca, Ascerta and Axio. JCB has consulted with Acerta, AstraZeneca, Pharmacyclics, Astellas, Syndax, and Jazz Pharmaceuticals and has stock ownership in Vincerx Pharmaceutics. JAW has consulted with Abbvie, AstraZeneca, Beigene, Janssen, Pharmacyclics, Loxo, and Newave, receives research funding from Morphosys, Karyopharm, Pharmacyclics, Janssen, and Schrodinger.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sigmund, A.M., Huang, Y., Ruppert, A.S. et al. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia 36, 2129–2131 (2022). https://doi.org/10.1038/s41375-022-01640-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-022-01640-y

Search

Quick links